BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 32901856)

  • 1. Determination of the migration effect and molecular docking of verteporfin in different subtypes of breast cancer cells.
    Wei C; Li X
    Mol Med Rep; 2020 Nov; 22(5):3955-3961. PubMed ID: 32901856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Verteporfin inhibits cell proliferation and induces apoptosis in different subtypes of breast cancer cell lines without light activation.
    Wei C; Li X
    BMC Cancer; 2020 Oct; 20(1):1042. PubMed ID: 33121449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Verteporfin inhibits growth of human glioma in vitro without light activation.
    Al-Moujahed A; Brodowska K; Stryjewski TP; Efstathiou NE; Vasilikos I; Cichy J; Miller JW; Gragoudas E; Vavvas DG
    Sci Rep; 2017 Aug; 7(1):7602. PubMed ID: 28790340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Verteporfin induces apoptosis and reduces the stem cell-like properties in Neuroblastoma tumour-initiating cells through inhibition of the YAP/TAZ pathway.
    Fusco P; Mattiuzzo E; Frasson C; Viola G; Cimetta E; Esposito MR; Tonini GP
    Eur J Pharmacol; 2021 Feb; 893():173829. PubMed ID: 33347823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet‑derived growth factor‑BB mediates pancreatic cancer malignancy via regulation of the Hippo/Yes‑associated protein signaling pathway.
    Li T; Guo T; Liu H; Jiang H; Wang Y
    Oncol Rep; 2021 Jan; 45(1):83-94. PubMed ID: 33416116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Verteporfin can Reverse the Paclitaxel Resistance Induced by YAP Over-Expression in HCT-8/T Cells without Photoactivation through Inhibiting YAP Expression.
    Pan W; Wang Q; Zhang Y; Zhang N; Qin J; Li W; Wang J; Wu F; Cao L; Xu G
    Cell Physiol Biochem; 2016; 39(2):481-90. PubMed ID: 27383277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Verteporfin exhibits anti-proliferative activity in embryonal and alveolar rhabdomyosarcoma cell lines".
    Sanna L; Piredda R; Marchesi I; Bordoni V; Forcales SV; Calvisi DF; Bagella L
    Chem Biol Interact; 2019 Oct; 312():108813. PubMed ID: 31494105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinically used photosensitizer Verteporfin (VP) inhibits YAP-TEAD and human retinoblastoma cell growth in vitro without light activation.
    Brodowska K; Al-Moujahed A; Marmalidou A; Meyer Zu Horste M; Cichy J; Miller JW; Gragoudas E; Vavvas DG
    Exp Eye Res; 2014 Jul; 124():67-73. PubMed ID: 24837142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Verteporfin exhibits YAP-independent anti-proliferative and cytotoxic effects in endometrial cancer cells.
    Dasari VR; Mazack V; Feng W; Nash J; Carey DJ; Gogoi R
    Oncotarget; 2017 Apr; 8(17):28628-28640. PubMed ID: 28404908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Features of the YAP Inhibitor Verteporfin: Synthesis of Hexasubstituted Dipyrrins as Potential Inhibitors of YAP/TAZ, the Downstream Effectors of the Hippo Pathway.
    Gibault F; Bailly F; Corvaisier M; Coevoet M; Huet G; Melnyk P; Cotelle P
    ChemMedChem; 2017 Jun; 12(12):954-961. PubMed ID: 28334506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Verteporfin inhibits YAP-induced bladder cancer cell growth and invasion via Hippo signaling pathway.
    Dong L; Lin F; Wu W; Liu Y; Huang W
    Int J Med Sci; 2018; 15(6):645-652. PubMed ID: 29725256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Verteporfin-loaded microparticles for radiosensitization of preclinical lung and breast metastatic spine cancer.
    Akinduro OO; Suarez-Meade P; Roberts M; Tzeng SY; Sarabia-Estrada R; Schiapparelli P; Norton ES; Gokaslan ZL; Anastasiadis PZ; Guerrero-Cázares H; Green JJ; Quiñones-Hinojosa A
    J Neurosurg Spine; 2023 Apr; 38(4):481-493. PubMed ID: 36585863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Yes-Associated Protein by Verteporfin Ameliorates Unilateral Ureteral Obstruction-Induced Renal Tubulointerstitial Inflammation and Fibrosis.
    Jin J; Wang T; Park W; Li W; Kim W; Park SK; Kang KP
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33142952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Doublecortin-like kinase 1 activates Hippo pathway to promote migration, invasion and proliferation of pancreatic cancer cells].
    Yan R; Liang ZW; Liu HS; Ge Y; An GY
    Zhonghua Zhong Liu Za Zhi; 2023 Jul; 45(7):594-604. PubMed ID: 37462016
    [No Abstract]   [Full Text] [Related]  

  • 15. Antiproliferative and Antimigratory Effects of a Novel YAP-TEAD Interaction Inhibitor Identified Using in Silico Molecular Docking.
    Smith SA; Sessions RB; Shoemark DK; Williams C; Ebrahimighaei R; McNeill MC; Crump MP; McKay TR; Harris G; Newby AC; Bond M
    J Med Chem; 2019 Feb; 62(3):1291-1305. PubMed ID: 30640473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-Photoinduced Biological Properties of Verteporfin.
    Gibault F; Corvaisier M; Bailly F; Huet G; Melnyk P; Cotelle P
    Curr Med Chem; 2016; 23(11):1171-84. PubMed ID: 26980565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. YAP activation is an early event and a potential therapeutic target in liver cancer development.
    Perra A; Kowalik MA; Ghiso E; Ledda-Columbano GM; Di Tommaso L; Angioni MM; Raschioni C; Testore E; Roncalli M; Giordano S; Columbano A
    J Hepatol; 2014 Nov; 61(5):1088-96. PubMed ID: 25010260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Verteporfin suppresses cell survival, angiogenesis and vasculogenic mimicry of pancreatic ductal adenocarcinoma via disrupting the YAP-TEAD complex.
    Wei H; Wang F; Wang Y; Li T; Xiu P; Zhong J; Sun X; Li J
    Cancer Sci; 2017 Mar; 108(3):478-487. PubMed ID: 28002618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Verteporfin regulates corneal neovascularization through inhibition of YAP protein activation.
    Lin L; Zheng Y; Li Q; Sun Y; Huang Y; Liang L; Xu L; Zhao YE
    Exp Eye Res; 2024 Jan; 238():109747. PubMed ID: 38072353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-invasive efficacy and survival benefit of the YAP-TEAD inhibitor verteporfin in preclinical glioblastoma models.
    Barrette AM; Ronk H; Joshi T; Mussa Z; Mehrotra M; Bouras A; Nudelman G; Jesu Raj JG; Bozec D; Lam W; Houldsworth J; Yong R; Zaslavsky E; Hadjipanayis CG; Birtwistle MR; Tsankova NM
    Neuro Oncol; 2022 May; 24(5):694-707. PubMed ID: 34657158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.